Publications
Detailed Information
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, Hyun-Jin | - |
dc.contributor.author | Kim, Hwang-Phill | - |
dc.contributor.author | Yoon, Young-Kwang | - |
dc.contributor.author | Hur, Hyung-Seok | - |
dc.contributor.author | Song, Sang-Hyun | - |
dc.contributor.author | Kim, Maeng-Sup | - |
dc.contributor.author | Lee, Gwan-Sun | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:00:35Z | - |
dc.date.available | 2021-01-31T11:00:35Z | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.issued | 2011-03-28 | - |
dc.identifier.citation | Cancer Letters, Vol.302 No.2, pp.155-165 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.other | 119682 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172959 | - |
dc.description.abstract | Trastuzumab, a HER2 directed treatment has shown clinical benefit in HER2 amplified gastric cancer. This study demonstrated the potent antitumor activity of HM781-36B, a quinazoline-based irreversible pan-HER inhibitor, in HER2 amplified gastric cancer cells (SNU216 and N87) in vitro and in vivo. HM781-36B inhibited phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest. Furthermore, HM781-36B exerted synergistic effects with chemotherapeutic agents in both HER2 amplified and HER2 non-amplified gastric cancer cells. Therefore, HM781-36B may be useful for the treatment of HER2 amplified gastric cancer alone or in combination with chemotherapeutic agents. (C) 2011 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1016/j.canlet.2011.01.010 | - |
dc.citation.journaltitle | Cancer Letters | - |
dc.identifier.wosid | 000288357300010 | - |
dc.identifier.scopusid | 2-s2.0-79951580512 | - |
dc.citation.endpage | 165 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 155 | - |
dc.citation.volume | 302 | - |
dc.identifier.sci | 000288357300010 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | HUMAN-BREAST-CANCER | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordAuthor | HM781-36B | - |
dc.subject.keywordAuthor | Pan-HER inhibitor | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Antitumor activity | - |
dc.subject.keywordAuthor | Chemotherapeutic agents | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.